Vaxart reduces authorized common stock and reverse stock split ratio to maintain Nasdaq listing.

From Nasdaq: 2025-05-16 18:14:00

Vaxart, Inc. (VXRT) announced key amendments to its proxy statement for the Annual Meeting. The board approved a reduction in authorized common stock in line with a 1-for-20 reverse stock split ratio, pending shareholder approval. These changes aim to maintain Vaxart’s Nasdaq listing and support share liquidity. Shareholders who previously voted against Proposal #2 can revise their votes before the May 20 deadline. VXRT closed at $0.5051, up 18.99%, with after-hours trading at $0.51 on the Nasdaq Capital Market. CEO Steven Lo emphasized the importance of the Nasdaq listing for advancing the company’s oral pill vaccine technology.



Read more at Nasdaq: Vaxart Limits Reverse Stock Split To 1-for-20 In Response To Shareholder Feedback